According to a literature survey, The annual incidence of pediatric LGGs is 1.5 to 2.35 per 100,000 in the US, estimated to be ~1,550 to 1,950 new diagnoses in 2019. Adult LGG is more common and is estimated to occur at a rate of 9.5 to 13.2 cases per 100,000 individuals in the US, and accounted for ~5,750 new diagnoses in 2019
Comprehensive insight on patient segmentation based on age, sex, Histopathologic Subtypes (Grade I & II), subtypes (Glial Tumors; PA, SGCA, DA, PX, OG, Mixed Glioneuronal Tumors; Ganglioglioma, DI-AG, DNT, PGT, RGT, AG, PLNTY, MVNT), Biomarkers (KIAA1549–BRAF, BRAF, NF1, FGFR1/2, RTK, MAPK, ALK/ROS1/NTRK, MEK & Others), Location (CH, Optic-pathway, Brain stream, Spine, ED, Cerebellum), Signs & Symptoms, Clinical Manifestations, Treatment types (Surgery; GTR, NO GTR, Chemotherapy, Radiation therapy & other investigational therapy) has been provided into the epidemiology section of the pLGG and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Day One Biopharmaceuticals, Inc., Hoffmann-La Roche, Novartis Pharmaceuticals, Agios Pharmaceuti-cals, Inc., Celldex Therapeutics, Millennium Pharmaceuticals, Inc., Janssen Pharmaceuticals, BeiGene USA, Inc., Daiichi Sankyo Co., Ltd., Boehringer Ingelheim who are targeting the Pediatric Low-grade gliomas (pLGG) market.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,